{"id":"W2997875868","doi":"10.1111/bjd.18851","title":"A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":172,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada); Dalhousie University; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Double blinded; Plaque psoriasis; Psoriasis; Randomized controlled trial; Dermatology; Head start; Internal medicine; Placebo; Secukinumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061431,0.0003145412,0.002874032,0.0005152784,0.0000763768,0.00002307089,0.0003205462,0.0004518167,0.0001081243],"category_scores_gemma":[0.0002984092,0.00028926,0.0002432545,0.0002480212,0.0001954039,0.0001556459,0.00009060144,0.0004011841,0.00002737055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006909575,"about_ca_system_score_gemma":0.0003153586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005758945,"about_ca_topic_score_gemma":0.0006243638,"domain_scores_codex":[0.9954565,0.001752703,0.001838995,0.000369711,0.000157987,0.0004241036],"domain_scores_gemma":[0.996918,0.001372,0.001015862,0.0002723416,0.0003181894,0.0001036053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9611276,0.001837118,0.02557157,0.0000293129,0.001162329,0.0001626043,0.001523582,0.0001508387,0.0007775465,0.00001763339,0.0002856195,0.007354239],"study_design_scores_gemma":[0.8613436,0.00292128,0.1259092,0.0006608532,0.0003960471,0.001625114,0.0002219776,0.00001058662,0.006345562,0.00003294744,0.000246415,0.0002864185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949307,0.00186358,0.00008661395,0.0003386378,0.0007480026,0.001771112,0.000199866,0.00001178716,0.00004965161],"genre_scores_gemma":[0.9990929,0.0001362796,0.0005199411,0.00006451967,0.00002607935,0.0000137852,0.00006792432,0.00002988431,0.00004868094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1003376,"threshold_uncertainty_score":0.999956,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01955120370552401,"score_gpt":0.2670848621733414,"score_spread":0.2475336584678174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}